NLS Pharmaceutics to Present at the LD Micro Virtual Invitational Conference on June 10, 2021

Rhea-AI Summary

NLS Pharmaceutics Ltd. (NASDAQ: NLSP) will present a corporate overview at the LD Micro Virtual Invitational Conference from June 8-10, 2021. CEO Alex Zwyer is set to deliver the presentation on June 10 at 11:30 AM ET on Track 2. The company's lead product, Quilience®, a controlled-release formulation of mazindol, is designed to treat narcolepsy and has received Orphan Drug Designations in both the U.S. and Europe. NLS completed a successful Phase 2 study on mazindol CR for ADHD, meeting all study endpoints.

STANS, Switzerland, June 2, 2021 /PRNewswire/ -- NLS Pharmaceutics Ltd. (NASDAQ: NLSP) (NASDAQ: NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage pharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, announces that Alex Zwyer, Chief Executive Officer and Co-Founder, is scheduled to present a corporate overview at the LD Micro Virtual Invitational Conference being held on
June 8 – June 10, 2021. 

Mr. Zwyer will deliver his corporate presentation on June 10 at 11:30am ET, Track 2 and the presentation can be viewed here. Investors attending the conference and interested in scheduling a meeting with management should contact assistant@ldmicro.com.

About NLS Pharmaceutics Ltd.

NLS Pharmaceutics Ltd. is a Swiss-based clinical-stage biopharmaceutical company led by an experienced management team with a track record of developing and repurposing product candidates to treat rare and complex central nervous system disorders. The Company's lead product candidate, Quilience® is a proprietary controlled-release formulation of mazindol (mazindol CR), and is being developed for the treatment of narcolepsy. Mazindol is a triple monoamine reuptake inhibitor and partial orexin receptor 2 agonist, which was used for many years to treat patients diagnosed with narcolepsy in compassionate use programs. NLS completed a phase 2 study in the U.S. evaluating mazindol CR in adult subjects with ADHD. The study met all primary and secondary endpoints and was well-tolerated. Quilience has received Orphan Drug Designations both in the U.S. and in Europe for the treatment of narcolepsy.

Corporate Contact
Alex Zwyer, CEO: +41 41 618 80 00 

Investor Relations Contact
Cindy Rizzo: +1 908-229-7050 

www.nlspharma.com

View original content to download multimedia:http://www.prnewswire.com/news-releases/nls-pharmaceutics-to-present-at-the-ld-micro-virtual-invitational-conference-on-june-10-2021-301302766.html

SOURCE NEUROLIFESCIENCES

FAQ

When is NLS Pharmaceutics scheduled to present at the LD Micro Virtual Invitational Conference?

NLS Pharmaceutics is scheduled to present on June 10, 2021, at 11:30 AM ET.

What is the focus of NLS Pharmaceutics as a company?

NLS Pharmaceutics focuses on developing innovative therapies for rare and complex central nervous system disorders.

What is Quilience and its purpose in NLS Pharmaceutics' pipeline?

Quilience® is a controlled-release formulation of mazindol being developed for treating narcolepsy.

Did NLS Pharmaceutics complete any clinical studies for its products?

Yes, NLS completed a Phase 2 study for mazindol CR in treating ADHD, which met all primary and secondary endpoints.

Which designations has Quilience received from regulatory bodies?

Quilience has received Orphan Drug Designations in both the U.S. and Europe for the treatment of narcolepsy.